Jennison Associates LLC Acquires New Holdings in uniQure N.V. $QURE

Jennison Associates LLC acquired a new stake in shares of uniQure N.V. (NASDAQ:QURE) during the second quarter, HoldingsChannel reports. The fund acquired 140,060 shares of the biotechnology company’s stock, valued at approximately $1,952,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in QURE. Mraz Amerine & Associates Inc. bought a new position in uniQure during the first quarter valued at approximately $106,000. Diamond Hill Capital Management Inc. lifted its position in uniQure by 22.8% during the first quarter. Diamond Hill Capital Management Inc. now owns 82,653 shares of the biotechnology company’s stock valued at $876,000 after purchasing an additional 15,333 shares during the period. XTX Topco Ltd lifted its position in uniQure by 127.3% during the first quarter. XTX Topco Ltd now owns 36,999 shares of the biotechnology company’s stock valued at $392,000 after purchasing an additional 20,720 shares during the period. Charles Schwab Investment Management Inc. lifted its position in uniQure by 3.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 279,999 shares of the biotechnology company’s stock valued at $2,968,000 after purchasing an additional 10,019 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in uniQure during the first quarter valued at approximately $3,218,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 0.3%

Shares of QURE stock opened at $67.69 on Friday. uniQure N.V. has a 12 month low of $5.35 and a 12 month high of $71.50. The stock has a market cap of $3.71 billion, a P/E ratio of -17.27 and a beta of 0.56. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The company has a 50 day simple moving average of $40.74 and a two-hundred day simple moving average of $23.65.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. UBS Group set a $95.00 price objective on shares of uniQure in a research report on Thursday, September 25th. Leerink Partners increased their price objective on shares of uniQure from $48.00 to $68.00 and gave the company an “outperform” rating in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of uniQure in a report on Wednesday, October 8th. Chardan Capital upped their target price on shares of uniQure from $35.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Finally, Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $71.75.

Insiders Place Their Bets

In other news, CEO Matthew C. Kapusta sold 226,316 shares of the stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total value of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at $27,009,282.84. This represents a 25.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Christian Klemt sold 15,000 shares of the stock in a transaction on Friday, September 26th. The stock was sold at an average price of $55.00, for a total transaction of $825,000.00. Following the completion of the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. This trade represents a 6.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 244,316 shares of company stock valued at $10,328,181. Corporate insiders own 4.79% of the company’s stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.